CT-95 in Advanced Cancers Associated With Mesothelin Expression

Launched by CONTEXT THERAPEUTICS INC. · Dec 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called CT-95 for patients with advanced cancers that express a protein called mesothelin. Mesothelin is found in certain types of tumors, including advanced ovarian cancer, lung cancer, and pancreatic cancer, among others. This trial aims to see how safe and effective CT-95 is for treating these cancers. It is currently open for patients aged 65 and older who have specific types of advanced solid tumors that can be measured by doctors.

To participate, patients should have good overall health, meaning they can carry out daily activities with little to no assistance. However, those with serious infections or who have received certain prior treatments for their cancer might not be eligible. Participants in the trial will receive CT-95 and will be closely monitored for any side effects and how well the treatment works. This study is important as it could provide new options for patients with challenging cancers that have limited treatment choices.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ECOG 0 or 1
• • Subjects with evaluable disease per RECIST 1.1 or mRECIST
• • Subjects with adequate organ function.
• • Subjects with advanced cancers associated with mesothelin expression
• Exclusion Criteria:
• • Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study.
• • Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy
• • Concurrent participation in another investigational clinical trial.
• • Evidence of leptomeningeal disease